Catalog No.
Product Name
Application
Product Information
Citations
-
CDK7 Inhibitor
CDK7-IN-28 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7) with an IC50 value of less than 5 nM. This compound effectively impedes cell proliferation in the MDA-MB-468 cell line by interfering with cell cycle progression and inhibiting DNA replication. Its activity makes it a valuable tool for research into cell cycle regulation and cancer therapeutics. -
CDK2 Inhibitor
CDK2-IN-37 is a selective cyclin-dependent kinase 2 (CDK2) inhibitor that demonstrates significant anti-cancer properties. By effectively inhibiting CDK2 activity, it disrupts cell cycle progression and promotes apoptosis in cancer cells. This compound is a valuable tool for researchers investigating the role of CDK2 in cancer biology and therapeutic development. -
CDK7 Inhibitor
(E/Z)-THZ1 dihydrochloride is a potent and selective inhibitor of Cyclin-Dependent Kinase 7 (CDK7) with an IC50 value of 3.2 nM. This compound exhibits significant antiproliferative activity, making it a valuable tool for research in cancer biology and cell cycle regulation. Its ability to inhibit CDK7 can be utilized in studies aimed at understanding transcriptional regulation and therapeutic strategies for various malignancies. -
CDK Inhibitor
(S)-(-)-O-Demethylbuchenavianine is a flavonoidal alkaloid that functions as a potent inhibitor of cyclin-dependent kinases (CDKs), specifically targeting CDK1 and CDK5 with IC50 values of 0.03 and 0.05 μM, respectively. This compound is valuable for research applications focused on cell cycle regulation and the investigation of CDK-related signaling pathways. Its inhibitory activity makes it an important tool for studying the role of CDKs in various biological processes and diseases. -
CDK
CDK4-IN-1 is a selective inhibitor of Cyclin-dependent kinase 4 (CDK4), exhibiting an IC50 of 10 nM. This compound demonstrates significant specificity, being 1500-fold and 500-fold less potent against CDK1/Cyclin B and CDK2/Cyclin A, respectively, with IC50 values greater than 15 µM and 5 µM. CDK4-IN-1 is primarily utilized in research focused on cell cycle regulation and anti-cancer therapies, particularly in the context of cancers characterized by aberrant CDK4 activity. -
CDK4/6 Inhibitor
Palbociclib dihydrochloride is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) with IC50 values of 11 nM and 16 nM, respectively. This compound exhibits significant anti-proliferative effects and induces cell cycle arrest in various cancer cell lines. It is particularly relevant for research applications in hormone receptor-positive and HER2-negative breast cancer, as well as hepatocellular carcinoma, providing insights into tumor growth regulation and potential therapeutic strategies. -
CDK4/6 Inhibitor
Palbociclib orotate is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), demonstrating IC50 values of 11 nM and 16 nM, respectively. This compound exhibits significant anti-proliferative activity, effectively inducing cell cycle arrest in cancer cells. Palbociclib orotate is primarily utilized in research focused on HR-positive and HER2-negative breast cancer as well as hepatocellular carcinoma, making it a valuable tool for understanding therapeutic strategies in these malignancies. -
CDK1 Inhibitor
CDK1-IN-5 is a selective inhibitor of cyclin-dependent kinase 1 (CDK1), demonstrating IC50 values of 42.19 nM for CDK1, 188.71 nM for CDK2, and 354.15 nM for CDK5. By targeting CDK1, this compound effectively disrupts cell cycle progression and inhibits the growth of cancer cells. CDK1-IN-5 is valuable for research applications focused on cancer biology and therapeutic strategies against tumor proliferation. -
CDK4 Inhibitor
Cimpuciclib is a selective inhibitor of cyclin-dependent kinase 4 (CDK4), exhibiting an IC50 value of 0.49 nM. This compound demonstrates significant anti-tumor activity, making it a valuable tool for cancer research. Its inhibition of CDK4 disrupts cell cycle progression, thus providing insights into therapeutic strategies for tumors driven by CDK4 dysregulation. -
CDK1 Inhibitor
CDK1-IN-3 is a selective inhibitor of Cyclin-dependent kinase 1 (CDK1), exhibiting IC50 values of 36.8 nM, 305.17 nM, and 369.37 nM for CDK1, CDK2, and CDK5, respectively. This compound effectively disrupts the cell cycle, leading to inhibition of cancer cell proliferation. CDK1-IN-3 is valuable for research applications targeting cancer biology and therapeutic development in oncology. -
CDK4/2 Inhibitor
GDC-4198 is an orally active inhibitor of cyclin-dependent kinases 4 and 2 (CDK4/2), exhibiting selective activity against kinases such as CDK6, CDK9, and GSK3β. By inhibiting cyclin-CDK complexes, GDC-4198 effectively blocks the phosphorylation of retinoblastoma protein (pRb), thus halting the cell cycle progression from the G1 to S phase. This compound is a valuable tool for investigating various cancers, particularly breast cancer (especially hormone receptor-positive, HER2-negative), lung cancer, and colorectal cancer. -
CDK Inhibitor
CDK7-IN-2 hydrochloride hydrate is a selective inhibitor of cyclin-dependent kinase 7 (CDK7). This compound demonstrates significant anti-cancer activity by inhibiting CDK7, which is crucial for cell cycle regulation and transcriptional control. CDK7-IN-2 is primarily used in cancer research to explore its therapeutic potential in various malignancies and to investigate CDK-driven signaling pathways. -
CDK7 Inhibitor
BS-181 dihydrochloride is a highly selective inhibitor of cyclin-dependent kinase 7 (CDK7) with an IC50 of 21 nM, showcasing superior potency compared to alternative compounds. It also exhibits moderate inhibition against CDK2, CDK5, and CDK9, with IC50 values of 880 nM, 3000 nM, and 4200 nM, respectively. BS-181 dihydrochloride has demonstrated the ability to inhibit the growth of various cancer cell lines (IC50 range of 11.5 μM to 37.3 μM) and to induce apoptosis. This compound is valuable for research applications focused on cancer therapies targeting CDK pathways. -
CDK4/CDK6 Inhibitor
CDK4/6-IN-3 is a potent inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), demonstrating Ki values of less than 0.3 nM and 2.2 nM, respectively. This compound also exhibits inhibitory activity against CDK1 with a Ki of 110 nM. Its ability to penetrate the blood-brain barrier makes CDK4/6-IN-3 a valuable candidate for research into glioblastoma therapies and other malignancies driven by dysregulated cell cycle progression. -
CDK9 Inhibitor
CDK9-IN-9 is a selective inhibitor of cyclin-dependent kinase 9 (CDK9), exhibiting an IC50 of 1.8 nM. This compound also demonstrates some activity against CDK2, with an IC50 of 155 nM. CDK9-IN-9 has been shown to possess anti-cancer properties, making it a valuable tool for research applications focused on cancer biology and therapeutic development targeting transcriptional regulation mechanisms. -
CDK7 Inhibitor
CDK7-IN-11 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7), demonstrating a high inhibitory activity with an IC50 value of 4.2 nM. This compound is suitable for in-depth research into diseases linked to CDK7 activity, providing valuable insights into its role in cell cycle regulation and transcriptional control. CDK7-IN-11 can aid in the exploration of therapeutic strategies targeting CDK7 in various malignancies and other pathological conditions. -
CDK9 Inhibitor
CDK9-IN-29 is a highly selective inhibitor of Cyclin-dependent kinase 9 (CDK9) with an IC50 value of 3.20 nM. This compound effectively hinders cell proliferation and promotes apoptosis in various cellular models. CDK9-IN-29 is suitable for research focused on cancer biology, particularly studies investigating transcriptional regulation and cell cycle dynamics. -
CDK Inhibitor
Tanuxiciclib trihydrochloride is a potent inhibitor of cyclin-dependent kinases (CDKs), which play a crucial role in cell cycle regulation. By selectively targeting CDK activity, this compound exhibits significant potential in impeding tumor cell proliferation. It is particularly valuable for research applications in cancer biology and therapeutic development, aiding in the exploration of CDK-related pathways and their implications in oncogenesis. -
CDK Inhibitor
Riviciclib is a potent cyclin-dependent kinase (CDK) inhibitor that selectively targets CDK9-cyclin T1, CDK4-cyclin D1, and CDK1-cyclin B, exhibiting IC50 values of 20 nM, 63 nM, and 79 nM, respectively. This compound demonstrates significant antitumor activity, especially in cisplatin-resistant cancer cells. Riviciclib is useful for research applications focused on cell cycle regulation, cancer therapy, and the development of resistance to chemotherapeutics. -
CDK Inhibitor
Cdc7-IN-3 is a selective inhibitor of the Cdc7 kinase, a serine-threonine protein kinase crucial for the initiation of DNA replication during the cell cycle. This compound demonstrates potent inhibitory activity against Cdc7, making it a valuable tool for studying cell proliferation and checkpoint control mechanisms. It is suitable for research applications involving cancer biology and the exploration of therapeutic strategies that target DNA replication processes. -
CDK6/9 Inhibitor
CDK6/9-IN-1 is a dual inhibitor of cyclin-dependent kinases 6 and 9, exhibiting IC50 values of 40.5 nM and 39.5 nM for CDK6 and CDK9, respectively. This compound demonstrates significant anti-proliferative activity, making it a valuable tool for studying cell cycle regulation and transcriptional control in various cancer models. It is particularly applicable in research focused on the therapeutic targeting of CDK pathways in oncogenesis. -
CDK Inhibitor
Tibremciclib is a selective inhibitor of cyclin-dependent kinase 4 (CDK4), exhibiting significant antineoplastic activity. By blocking CDK4 activity, it disrupts cell cycle progression and promotes apoptosis in cancer cells. Tibremciclib is primarily utilized in cancer research and therapeutic applications, focusing on targeting tumors driven by aberrant CDK4 signaling. -
CDK8/19 Inhibitor
Senexin A hydrochloride is a selective inhibitor of cyclin-dependent kinases 8 and 19 (CDK8 and CDK19), with an IC50 of 280 nM for CDK8. It specifically targets and inhibits p21-induced transcription, while sparing other biological functions of p21. In addition, Senexin A hydrochloride effectively suppresses CMV-GFP induction and the p21 stimulatory activity of NF-κB-dependent promoters, making it a valuable tool for studying transcriptional regulation and cell signaling pathways. -
CDK Inhibitor
Cdc7-IN-7 is a potent inhibitor of the Cdc7 kinase, a serine-threonine protein kinase critical for the initiation of DNA replication during the cell cycle. By selectively targeting Cdc7, this compound demonstrates significant potential in inhibiting cellular proliferation and tumor growth. Research applications include studies on cell cycle regulation, cancer biology, and potential therapeutic strategies in oncology. -
CDK2 Inhibitor
QR-6401 is a selective macrocyclic inhibitor of cyclin-dependent kinase 2 (CDK2), demonstrating an IC50 of 0.37 nM for CDK2/E1 and exhibiting varying activity against other CDKs. This compound shows potent antitumor efficacy in an OVCAR3 ovarian cancer xenograft model. QR-6401 is valuable for research into cancer mechanisms and potential therapeutic approaches targeting CDK2. -
CDK7 Inhibitor
CDK7-IN-6 is a potent and selective inhibitor of cyclin-dependent kinase 7 (CDK7), demonstrating an IC50 of less than 100 nM. This compound exhibits over 200-fold selectivity for CDK7 compared to CDK1, CDK2, and CDK5. CDK7-IN-6 is valuable for cancer research, providing a tool for investigating the role of CDK7 in cell cycle regulation and potential therapeutic strategies. -
CDK Inhibitor
AGM-130 is a selective cyclin-dependent kinase (CDK) inhibitor that interferes with cell cycle progression. It has demonstrated significant antitumor activity, making it a valuable tool for cancer research. This compound can be utilized in studies aimed at understanding CDK modulation and its potential therapeutic implications in oncology. -
CDK7 Inhibitor
CDK7-IN-16 is a selective inhibitor of cyclin-dependent kinase 7 (CDK7), demonstrating potent activity with an IC50 range of 1 to 10 nM. This compound is primarily utilized in cancer research, particularly in studies focused on malignancies characterized by transcriptional dysregulation. Its ability to modulate CDK7 activity makes it a valuable tool for investigating therapeutic strategies in oncology. -
CDK8 Inhibitor
CDK8-IN-6 is a potent inhibitor of cyclin-dependent kinase 8 (CDK8) with a Kd of 13 nM. This compound exhibits significant cytotoxic effects on various cancer cell lines, including MOLM-13, OCI-AML3, MV4-11, NRK, and H9c2, with IC50 values ranging from 7.5 to 25 µM. CDK8-IN-6 holds promise for advancing research in acute myeloid leukemia (AML) and related cancer studies, making it a valuable tool for investigating CDK8's role in tumorigenesis. -
CDK4/9 Inhibitor
CDK4/9-IN-1 is a selective dual inhibitor of cyclin-dependent kinases 4 and 9, exhibiting IC50 values of 23 nM for CDK4 and 12 nM for CDK9. This compound demonstrates significant potential in the study of cancer biology, particularly in elucidating the role of CDK4 and CDK9 in the cell cycle and transcription regulation. Researchers may utilize CDK4/9-IN-1 to investigate therapeutic strategies targeting these kinases in various cancer models. -
P25/CDK5 Inhibitor
DSS30 is a selective inhibitor of P25/CDK5, targeting the phosphorylation of amyloid precursor protein lyase 1 (BACEl). By inhibiting this phosphorylation, DSS30 effectively reduces the secretion of β-amyloid (Aβ), a key factor in the pathogenesis of Alzheimer's disease. This compound is valuable for research into neurodegenerative disorders and mechanisms underlying Aβ accumulation. -
CDK8 Inhibitor
CDK8-IN-17 is a potent inhibitor of cyclin-dependent kinase 8 (CDK8) with an IC50 value of 9 nM. This compound regulates transcriptional control and has demonstrated significant potential in cancer research by modulating oncogenic pathways. CDK8-IN-17 is valuable for studies investigating the role of CDK8 in tumorigenesis and therapeutic applications targeting cellular proliferation. -
CDK9 Inhibitor
CDK9-IN-31 is a selective inhibitor of cyclin-dependent kinase 9 (CDK9), which plays a critical role in regulating transcription and cell proliferation. By inhibiting CDK9, this compound demonstrates significant anti-cancer activity through the suppression of cancer cell growth. Its potential applications extend to cancer research, providing valuable insights into therapeutic strategies targeting transcriptional regulation in malignancies. -
CDK Inhibitor
CDK/HDAC-IN-1 is a potent inhibitor targeting cyclin-dependent kinases CDK2, CDK4, CDK6, and histone deacetylase 6 (HDAC6) with respective IC50 values of 60.9 ± 2.9 nM, 276 ± 22.3 nM, 27.2 ± 4.2 nM, and 128.6 ± 0.4 nM. This dual-action compound demonstrates significant biological activity in inhibiting cell cycle progression and modulating gene expression. CDK/HDAC-IN-1 is suitable for research applications exploring cancer biology, epigenetic regulation, and therapeutic strategies targeting CDK and HDAC pathways. -
CDK7 Inhibitor
CDK7-IN-10 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7), with an IC50 value of less than 100 nM. This compound effectively inhibits kinase activity, leading to reduced cell proliferation and the induction of apoptosis in various cell types. CDK7-IN-10 is valuable for research applications focused on cancer biology and therapeutic development targeting cell cycle regulation. -
CDK9 Inhibitor
CDK9-IN-38 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), exhibiting IC50 values of 1.2 nM for the wild-type enzyme and 3.3 nM for the L156F mutant variant. This compound has demonstrated significant inhibitory effects on tumor growth in both in vitro and in vivo models. CDK9-IN-38 is a valuable tool for research into the regulation of transcriptional control and the therapeutic potential for cancer treatment. -
CDK4/6 Inhibitor
CDK4/6-IN-7 is a potent and selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), with IC50 values of 1.58 nM and 4.09 nM, respectively. This orally active compound demonstrates significant biological activity, making it a valuable tool for investigating the role of CDK4/6 in various cancer models, particularly in breast cancer research. Its specificity and efficacy support studies aimed at understanding and targeting cell cycle progression in tumor cells. -
CDK4/6 Inhibitor
PF-06842874 is a selective inhibitor of CDK4 and CDK6, targeting the cyclin D1 and cyclin D3 complexes with Ki values of 62 nM and 130 nM, respectively. This compound demonstrates significant biological activity in the inhibition of cell proliferation, making it a valuable tool in cancer research and the study of pulmonary arterial hypertension. Its ability to modulate cell cycle progression positions PF-06842874 as an important reagent for investigating therapeutic strategies in oncological and vascular disease contexts. -
CDK7 Inhibitor
CDK7-IN-32 is a potent inhibitor of Cyclin-dependent kinase 7 (CDK7), a key regulator of cell cycle progression and transcriptional regulation. This compound effectively disrupts CDK7 activity, leading to decreased phosphorylation of its substrates and subsequent modulation of cellular proliferation and survival. CDK7-IN-32 is utilized in cancer research and studies investigating the role of CDK7 in transcriptional control and therapeutic resistance. -
CDK9 Inhibitor
CDK9-IN-28 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9), which plays a critical role in regulating transcription and cell cycle progression. This compound exhibits strong anti-proliferative effects, particularly in solid tumor models, making it valuable for cancer research. Additionally, CDK9-IN-28 serves as a target protein ligand for the synthesis of PROTACs, aiding in the development of innovative therapeutic strategies for targeting CDK9-dependent pathways. -
CDK1/CDK2 Inhibitor
LZ9 is an ATP-competitive inhibitor of CDK1 and CDK2. This compound demonstrates significant biological activity in inhibiting cyclin-dependent kinases, making it a valuable tool for investigating cell cycle regulation. LZ9 has potential applications in research focused on colorectal cancer (CRC), aiding in the exploration of therapeutic strategies targeting this malignancy. -
CDK9 Inhibitor
CDK9-IN-49 is a potent inhibitor of Cyclin-dependent kinase 9 (CDK9) with an IC50 of 7.32 nM. This compound effectively suppresses the proliferation of various cancer cell lines, making it a valuable tool for cancer research. CDK9-IN-49 is particularly relevant for studies focused on acute myeloid leukemia and prostate cancer, facilitating investigations into therapeutic strategies targeting CDK9 pathways. -
CDK4/6 Inhibitor
CDK4/6-IN-24 is a potent inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), key regulators of the cell cycle. This compound demonstrates broad-spectrum antitumor activity across various cancer cell lines, with IC50 values in the submicromolar range. CDK4/6-IN-24 is a valuable tool for researchers investigating cell cycle regulation and therapeutic strategies for cancer treatment. -
CDK2 Inhibitor
CDK2-IN-54 is a selective inhibitor of cyclin-dependent kinase 2 (CDK2), a critical regulator of the cell cycle. This compound demonstrates potent anti-proliferative activity in various cancer types, including triple-negative breast cancer, ovarian cancer, bladder cancer, and uterine cancer. CDK2-IN-54 is valuable for research applications focused on understanding cell cycle dynamics and exploring therapeutic strategies in oncology. -
CDK9 PROTAC Degrader
PROTAC CDK9 degrader-11 is an orally active PROTAC degrader that specifically targets CDK9, demonstrating a DC50 value of 1.09 nM. This compound shows cytotoxicity in various small cell lung cancer cell lines with an IC50 in the nanomolar range. PROTAC CDK9 degrader-11 effectively induces cell cycle arrest at the G0/G1 phase and reduces invasion in DMS114 and DMS53 cells. Additionally, it exhibits significant antitumor efficacy in NCI-H446 xenograft mouse models, making it a valuable tool for cancer research and therapeutic development. -
CDK4/6 Inhibitor
CDK4/6-IN-21 maleate is a potent inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), exhibiting IC50 values of 3.88 nM and 3.31 nM against CDK4 and CDK6, respectively. This compound demonstrates significant antitumor activity, making it a valuable tool for research into cell cycle regulation and cancer therapeutics. Its targeted inhibition of CDK4/6 positions it as a key reagent for studying oncogenic pathways and developing new cancer treatment strategies. -
CDK4/CDK6 Inhibitor
CDK4/6-IN-20 is a potent inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/CDK6), demonstrating IC50 values of 1.9 nM and 14.2 nM, respectively. This compound effectively inhibits cell proliferation, making it a valuable tool for cancer research applications. Its selective inhibition of CDK4/6 contributes to understanding cell cycle regulation and potential therapeutic interventions in malignancies. -
CDK Iinhibitor
CGP-79807 is a purine-based inhibitor targeting cyclin-dependent kinases (CDKs). It effectively disrupts the cell cycle by inhibiting CDK activity, leading to the suppression of tumor cell proliferation. This compound is valuable in cancer research for exploring the mechanisms of cell cycle regulation and potential therapeutic strategies. -
CDK2/4/6 Inhibitor
CDK2/4/6-IN-1 is a potent inhibitor of cyclin-dependent kinases 2, 4, and 6, with IC50 values of 2.5 nM, 23.7 nM, and 44.3 nM, respectively. This compound is valuable for cancer research, allowing for the study of cell cycle regulation and tumor progression. Additionally, CDK2/4/6-IN-1 features an alkyne group enabling its use in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions, facilitating bioconjugation and labeling applications in chemical biology. -
CDK
[pThr3]-CDK5 Substrate is a specific substrate for cyclin-dependent kinase 5 (CDK5), functioning primarily through phosphorylation at threonine 3. This substrate is based on the histone H1 peptide sequence, which effectively binds within the active site of CDK5. It is phosphorylated by CDK5 with a Km value of 6 µM, making it useful for studies examining CDK5 activity and regulation in various biological contexts.
